Brief: Biorestorative Therapies Receives Unanimous Recommendation From Data Safety Monitoring Board To Continue Phase 2 Clinical Trial Without Any Changes
27/06/2023 12:59
June 27 (Reuters) - BioRestorative Therapies Inc
BRTX.O :
* BIORESTORATIVE THERAPIES RECEIVES UNANIMOUS RECOMMENDATION
FROM
DATA SAFETY MONITORING BOARD (DSMB) TO CONTINUE ITS PHASE 2
CLINICAL TRIAL WITHOUT ANY CHANGES
* BIORESTORATIVE THERAPIES INC - NO DOSE LIMITING TOXICITY
(DLT)
WAS OBSERVED IN PATIENTS IN SAFETY RUN-IN SEGMENT OF STUDY
Source text for Eikon: ID:nGNXbwf1Dq
Further company coverage: BRTX.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Biorestorative Therapies
See all newsBioRestorative Therapies Inc expected to post a loss of $2.50 a share - Earnings Preview
BioRestorative Therapies Inc expected to post a loss of $2.50 a share - Earnings Preview
NASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM